- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 92,510 | 08.07.24 16:09:05 | +1,470 | +1,61% | 0,000 | 0,000 | 91,200 | 91,040 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 960,200 | 08.07.24 11:52:24 | +16,800 | +1,78% | 0,000 | 0,000 | 951,400 | 943,400 |
